Retention of baricitinib-treated patients with rheumatoid arthritis in Japan: Interim results from a prospective observational cohort study
Modern Rheumatology · 2026
DOI: 10.1093/mr/roaf113 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Modern Rheumatology, 2026. Verfasst von Yuko Kaneko und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan. Hauptthemen laut MEDLINE: Arthritis, Rheumatoid, Purines, Antirheumatic Agents, Pyrazoles. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Japan Drug Development & Medical Affairs, Eli Lilly Japan.
Abstract (Originalsprache)
Objectives
To assess the retention rate, changes in disease activity and patient-reported outcomes (PROs), and predictors of treatment discontinuation among baricitinib-treated patients with rheumatoid arthritis (RA) in routine clinical practice in Japan.
Methods
This ongoing, multi-centre, prospective, observational study (starting February 2021) included ≥20-year-old baricitinib-treated patients with RA. Baricitinib’s retention rate and effectiveness were evaluated until 12 months. The association between patient characteristics and retention was evaluated using Random Forest analysis.
Results
This interim analysis included 353 patients (mean [standard deviation; SD] age 63.4 [13.6] years; 70.0% female). The 12-month retention rate was 70.2% (95% confidence interval [CI] 65.1, 74.6). The 12-month remission rates were 35.3%, 41.1%, and 79.6% per Clinical Disease Activity Index, Simplified Disease Activity Index, and Disease Activity Score with 28 joints–C-reactive protein. The mean (SD) changes in PROs from baseline scores were: physician global assessment of disease activity (−33.8 [27.8]), patient global assessment of disease activity (−18.3 [29.4]), Health Assessment Questionnaire-Disability Index (−0.33 [0.53]), and pain (−19.4 [27.0]). Ten variables influenced the model’s prediction of treatment discontinuation.
Conclusions
Evidence from this interim analysis suggested the favourable effectiveness and drug survival of baricitinib in real-world Japanese patients with RA.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan.
- Japan Drug Development & Medical Affairs, Eli Lilly Japan K.K., Kobe, Japan.
- Department of Rheumatology/ Rheumatic Disease Center, Dokkyo Medical University, Tochigi, Japan.
ORCID-Profile: Yuko Kaneko, Chaochen Wang, Masaru Tanaka
Förderung
- Japan Drug Development & Medical Affairs, Eli Lilly Japan
Zitieren
APA
Kaneko, Y., Wang, C., Tsujimoto, N., Tanaka, M., & Ikeda, K. (2026). Retention of baricitinib-treated patients with rheumatoid arthritis in Japan: Interim results from a prospective observational cohort study. Modern Rheumatology. https://doi.org/10.1093/mr/roaf113
Vancouver
Kaneko Y, Wang C, Tsujimoto N, Tanaka M, Ikeda K. Retention of baricitinib-treated patients with rheumatoid arthritis in Japan: Interim results from a prospective observational cohort study. Modern Rheumatology. 2026. doi:10.1093/mr/roaf113
BibTeX
@article{Kaneko2026,
author = {Kaneko, Yuko and Wang, Chaochen and Tsujimoto, Naoto and Tanaka, Masaru and Ikeda, Kei},
title = {Retention of baricitinib-treated patients with rheumatoid arthritis in Japan: Interim results from a prospective observational cohort study},
journal = {Modern Rheumatology},
year = {2026},
doi = {10.1093/mr/roaf113}
}
EUVIMED